logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line

< Back

Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line

Drugs

Cancer and Palliative Care

November 2020


Polatuzumab vedotin in combination with rituximab and cyclophosphamide, doxorubicin, prednisone/prednisolone (R-CHP) chemotherapy is in clinical development for patients with diffuse large B-cell lymphoma (DLBCL) that has been untreated. DLBCL is a cancer affecting a type of white blood cells called lymphocytes or B-cells. DLBCL is an aggressive cancer and although it can be cured in more than half of people affected, it remains a serious and life-threatening disease, particularly when it relapses or does not respond to treatment.
Polatuzumab vedotin is a first-in-class drug specifically developed for the treatment of cancers that affect the blood and lymph system. It is an antibody that binds to CD79b, which is a protein on the surface of cancerous B-cells. It is administered as an intravenous infusion, absorbed by the cancer cells and the chemotherapy agent linked to the antibody releases inside the cancer cells, stops them from dividing and kills them. If licenced polatuzumab vedotin in addition to R-CHP would offer an additional treatment option for patients with untreated DLBCL.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts